US Stock MarketDetailed Quotes
KALA KALA BIO
- 7.6300
- +0.7600+11.06%
Close Nov 8 16:00 ET
35.16MMarket Cap-564P/E (TTM)
7.8400High6.8500Low156.50KVolume6.8500Open6.8700Pre Close1.16MTurnover5.62%Turnover RatioLossP/E (Static)4.61MShares10.970052wk High2.56P/B21.26MFloat Cap4.210052wk Low--Dividend TTM2.79MShs Float1337.5000Historical High--Div YieldTTM14.41%Amplitude3.5440Historical Low7.4270Avg Price1Lot Size
About KALA BIO Company
KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Company Profile
SymbolKALA
Company NameKALA BIO
Listing DateJul 20, 2017
Issue Price15.00
Founded2009
CEOMr. Mark T. Iwicki
MarketNASDAQ
Employees43
Fiscal Year Ends12-31
Address1167 Massachusetts Avenue
CityArlington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02476
Phone1-781-996-5252
Websitehttp://www.kalarx.com
Company Executives
-
Name
- Position
- Salary
-
Mark T. Iwicki
- Chairman of the Board and Chief Executive Officer
- 8.34M
-
Todd Bazemore
- Chief Operating Officer and President
- 2.94M
-
Dr. R. Kim Brazzell,PhD
- Head of Research and Development and Chief Medical Officer
- 2.92M
-
Mary Reumuth
- Chief Financial Officer, Treasurer, Corporate Secretary and Principal Accounting Officer
- --
-
Darius Kharabi
- Chief Business Officer
- --
-
Dr. Marjan Farid, M.D.
- Independent Director
- 225.64K
-
Howard B. Rosen
- Independent Director
- 392.20K
-
C. Daniel Myers
- Independent Director
- 236.94K
-
Andrew I. Koven
- Lead Independent Director
- 402.36K
-
Gregory D. Perry
- Independent Director
- 302.01K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
